Affiliations 

  • 1 Rheumatology Unit, Department of Medicine, Hospital Raja Permaisuri Bainun, Jalan Raja Ashman Shah, Ipoh, Perak, Malaysia
  • 2 Sector for Biostatistics & Data Repository, Office of NIH Manager, National Institutes of Health, Ministry of Health Malaysia, Selangor, Malaysia
  • 3 Faculty of Medicine, University Kuala Lumpur Royal College of Medicine Perak, Perak, Malaysia
Mediterr J Rheumatol, 2024 Jun;35(2):234-240.
PMID: 39211017 DOI: 10.31138/mjr.050723.fla

Abstract

OBJECTIVE: The aim of this study was to establish the incidence of liver abnormalities in psoriatic arthritis patients and identify the factors that contributed to this condition.

METHODS: This is a longitudinal cohort study. Psoriatic arthritis (PsA) patients with liver enzymes abnormalities were identified. Our control group consisted of PsA patient from the same cohort who had no history of liver abnormalities. Factors associated with liver abnormalities were identified using univariate and multivariate analysis.

RESULTS: A total of 247 of PsA patients were included and out of those, 99 developed liver enzymes abnormalities. The mean age of the patients was 56 years old (±13.5) with 56.1% female and 39.4% Indian descendants. The univariate logistic regression demonstrated that disease duration of PsA (OR=1.06, 95% CI=1.01 - 1.10, p=0.012), diabetes mellitus (OR=2.16, 95% CI=1.26 - 3.70, 0.005) and non-alcoholic fatty liver disease (NAFLD) (OR=3.90, 95% CI = 1.44 - 10.53, p=0.007) were associated with abnormal liver function in PsA patients. No association was found with both conventional synthetic disease-modifying antirheumatic drugs or biologics.

CONCLUSION: Liver enzymes abnormalities in PsA patients were linked to disease duration, diabetes mellitus and NAFLD. For these high-risk populations, vigilant monitoring of liver function tests is vital for early detection and intervention.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.